Home Contact
Login   |  Tell a Friend
Financial Optimization through Technology Innovation
mutual fund
 Top Fund Managers
Latest Mutual Fund News Latest Mutual Fund News

Financial Advisor Sponsor:Philip A. White


 Bookmark this site!
Follow FundMojo on Twitter
Get Fund Information

Get Stock News

(Enter Stock Symbol)

Partner Sites

Annuities
Wall Street Journal
eHealthInsurance
Fund Mojo on Facebook
Fund Mojo help you discover the best fund managers, funds, and related information

Fund Intelligence | Best Managers | CNCRX Insights | CNCRX Score | CNCRX Performance | CNCRX Manager | CNCRX News | CNCRX Allocation | CNCRX Holdings Change

Mutual Fund Insights: AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

In-depth Analysis of AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

Mutual fund chart: AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

3 months
6 months
1 year
3 year
5 year

See AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) performance details as of January 31, 2010

  

    Last Trade: $6.90 on 3/19/2010, Change: -0.01 (-0.14%)

  

Fund Manager - Gadi Beer

Fund Manager Tenure: 8.4 years
Fundmojo Fund Grade: D (Score: 0.44)     (What does this score mean?)
Beer is the chief operating officer of Index Investments LLC. He has served as research analyst and vice president since 1999.  Get more insights on Gadi Beer

  

What we like about AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) What we like about AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

Data for AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) as of January 31, 2010

  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) management has been with AMIDEX Cancer Innovation & Healthcare Fund for 8.4 years
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) has good Long-term performance (5-year return 4.93% vs 4.22% Health category average)
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) ratio of up-years vs down years is greater than 2
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) has a Morningstar rating of 4 and above
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) is less volatile than its peers as it has a 3-year Standard Deviation of 11.57, lower than category average of 18.84

  

What we are cautious about AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) What we are cautious about AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

Data for AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) as of January 31, 2010

  • AMIDEX Cancer Innovation & Healthcare Fund is a focused fund with 75.67% of the portfolio on top 10 securities. This tends to produce more volatility compared to a diversified fund. See fund top 10 holdings.
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) has a less-than-ideal short-term performance (1-year return 5.94% vs 24.07% Health category average)
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) has a less-than-ideal mid-term performance (3-year return -0.77% vs -0.24% Health category average)
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) is less safe compared to its Health peers
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) does not have a good risk adjusted return as its 3-year Alpha of 0.53 is worse than category average of 5.11, and its 3-year Sharpe ratio is -0.18
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) has a higher management fee of 5.13% than its Health average of 1.91%
  • AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) carries a 5.5% load
See AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) performance details as of January 31, 2010

  

  

Interested in other top mutual funds in similar Health category?

Below are some additional Health mutual funds generated out of our database

  

AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) Net Asset

Track net asset change of AMIDEX Cancer Innovation & Healthcare fund (CNCRX)

DateNet Asset
01/2010$740.00K
11/2009$830.00K
10/2009$790.00K
More historic net asset information on AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

  

AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) Portfolio Allocation

Track portfolio allocation change of AMIDEX Cancer Innovation & Healthcare fund (CNCRX)

DateCashStockBondOther
09/200945.66%54.34%0%0%
06/200951.6%48.4%0%0%
03/200959.6%40.4%0%0%
Click here to see more historic asset allocation information on AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

  

Most Recent Top 10 Holdings in AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

Discover what AMIDEX Cancer Innovation & Healthcare Fund (CNCRX) manager is buying

30-Sep-09
Fidelity Instl MM Fds Money Market Sel [45.66%]
Gilead Sciences, Inc. [5.14%]
Celgene Corporation [4.06%]
JOHNSON AND JOHNS DC [3.74%]
ASTRAZENECA PLC ADS [3.33%]
Biogen Idec Inc [3%]
WYETH [2.99%]
NOVARTIS AG ADS [2.73%]
VARIAN MED SYS INC [2.58%]
GLAXOSMITHKLINE PLC [2.44%]

30-Jun-09
Fidelity Instl MM Fds Money Market Sel [51.6%]
Gilead Sciences, Inc. [5.12%]
Celgene Corporation [3.49%]
JOHNSON AND JOHNS DC [3.45%]
ASTRAZENECA PLC ADS [3.22%]
WYETH [2.76%]
Biogen Idec Inc [2.61%]
Genzyme Corporation [2.34%]
ABBOTT LABORATORIES [2.29%]
NOVARTIS AG ADS [2.23%]

31-Mar-09
Gilead Sciences, Inc. [4.46%]
Celgene Corporation [2.85%]
Johnson & Johnson [2.81%]
Biogen Idec Inc [2.66%]
Wyeth [2.3%]
AstraZeneca Plc [2.27%]
Genzyme Corporation [2.2%]
Abbott Laboratories [2.04%]
Bristol-Myers Squibb Co. [1.88%]
Novartis AG Basel [1.82%]
Click here for Stock Holding Change Map in AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

  

Related books and products to AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

  

Latest News on AMIDEX Cancer Innovation & Healthcare (CNCRX)

See what is happening with AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)

 

Books and Resources

 

 

See more information on AMIDEX Cancer Innovation & Healthcare Fund (CNCRX)